Foghorn Therapeutics 2023 net loss $98.4M, cash $234.1M; FHD-909 IND planned Q2 2024

Foghorn Therapeutics Inc.

Net loss $98.4M in 2023 vs $108.9M in 2022; collaboration revenue $34.2M, up from $19.2M.
Cash $234.1M at Dec 31, 2023; runway into H1 2026.
FHD-286 AML combo study dose escalation ongoing; first clinical data expected H2 2024.
Lilly selects FHD-909 (BRM inhibitor) for clinical dev; IND filing Q2 2024 for BRG1-mutated NSCLC.
Preclinical data for CBP/EP300 degraders at AACR; IND-enabling studies for CBP degrader by end 2024.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Foghorn Therapeutics Inc. reported the year ended December 31, 2023 results: revenue $34.2 million.

Period: the year ended December 31, 2023
Revenue: $34.2 million
Result: reported results

Exact text from the filing

three discovery programs using Foghorn’s proprietary Gene Traffic Control platform. Full Year 2023 Financial Highlights • Collaboration Revenues . Collaboration revenues were $34.2 million for the year ended December 31, 2023, compared to $19.2 million for the year ended December 31, 2022. The increase year-over-year was primarily driven by revenue recognized under

View on SEC.gov

710 earnings releases filed in the last 30 days. Browse all earnings releases →

Foghorn Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-009540

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.